Pancreatic Cancer Research

ResearcherAzienda Ospedaliera Citta' della Salute e della Scienza di TorinoActive in the last 2 years

Claudia Curcio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5306-4399; OpenAlex author ID A5007215321. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers

Papers 11

  1. The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma. Co-author DOI 10.1002/ctm2.70442↗
  2. Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier. Last author DOI 10.3390/biom15050725↗
  3. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Co-author DOI 10.1186/s13046-024-03080-1↗
  4. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector r… Co-author DOI 10.3389/fimmu.2024.1427424↗
  5. Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality? Last author DOI 10.3390/cells13181558↗
  6. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer pat… Co-author DOI 10.1007/s10238-023-01236-5↗
  7. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. First author DOI 10.1073/pnas.2020395118↗
  8. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer. Co-author DOI 10.3390/molecules26061642↗
  9. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. First author DOI 10.1136/jitc-2020-001071↗
  10. Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. First author DOI 10.3390/cancers10020051↗
  11. Endogenous glutamine decrease is associated with pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.20545↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Silvia Brugiapaglia · 7 shared papers, 2021–2025 · strength 1.57
  2. Francesco Novelli · 10 shared papers, 2017–2025 · strength 1.50
  3. Paola Cappello · 8 shared papers, 2017–2025 · strength 1.08
  4. Cecilia Roux · 5 shared papers, 2017–2025 · strength 0.65
  5. Gianluca Mucciolo · 3 shared papers, 2021–2025 · strength 0.49
  6. Rosella Spadi · 3 shared papers, 2020–2024 · strength 0.41
  7. Francesca Cordero · 2 shared papers, 2020–2024 · strength 0.28
  8. Laura Follia · 2 shared papers, 2020–2021 · strength 0.25
  9. Giorgia Tiberi · 1 shared paper, 2025 · strength 0.20
  10. Giulia Adriani · 1 shared paper, 2025 · strength 0.20
  11. Giorgia Mandili · 2 shared papers, 2018–2020 · strength 0.19
  12. Judith A. Varner · 1 shared paper, 2024 · strength 0.18
  13. Claudio De Angelis · 1 shared paper, 2023 · strength 0.14
  14. Elisabetta Fenocchio · 1 shared paper, 2023 · strength 0.14
  15. Alessandro Ferrero · 1 shared paper, 2023 · strength 0.14
  16. Serena Langella · 1 shared paper, 2023 · strength 0.14
  17. Michela Capello · 1 shared paper, 2021 · strength 0.10
  18. Rita Teresa Lawlor · 1 shared paper, 2021 · strength 0.10
  19. Aldo Scarpa · 1 shared paper, 2021 · strength 0.10
  20. Moitza Principe · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.